Note 9 - Debt and Convertible Debt (Details) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended	39 Months Ended												9 Months Ended					1 Months Ended						1 Months Ended	9 Months Ended			1 Months Ended		12 Months Ended		30 Months Ended			1 Months Ended
	Mar. 31, 2011	Jun. 30, 2013	Sep. 30, 2012	Sep. 30, 2013		Sep. 30, 2013		Aug. 25, 2013	May 31, 2013	Dec. 31, 2012		May 31, 2011	Aug. 31, 2013 Tranche 1 [Member] Midcap [Member]	Aug. 31, 2013 Tranche 2 [Member] Midcap [Member]	Aug. 31, 2013 Tranche 1 and 2 [Member] Midcap [Member]	Sep. 30, 2013 Future Payment - 2014 [Member] Mablife [Member]	Sep. 30, 2013 Future Payment 2015 [Member] Mablife [Member]	Sep. 30, 2013 Future Payment 2016 [Member] Mablife [Member]	Sep. 30, 2013 Future Payment - 2017 [Member] Mablife [Member]	Aug. 31, 2011 Amendment - New Fair Value [Member]	Jun. 30, 2012 Cash Payment [Member] Chief Executive Officer [Member]	Aug. 31, 2011 Expected to be Issued [Member]	Aug. 31, 2011 Loan Extension [Member]	Dec. 31, 2011 Potential Share Buy-Back [Member] Private Investor [Member]	Dec. 31, 2010 Potential Share Buy-Back [Member] Three Private Investors [Member]	Sep. 30, 2013 Mablife [Member] Present Value [Member]	Apr. 30, 2012 Mablife [Member]	Sep. 30, 2013 Mablife [Member]	Sep. 30, 2012 Mablife [Member]	Mar. 31, 2012 Mablife [Member]	Jun. 30, 2012 Chief Executive Officer [Member]	Dec. 31, 2010 Chief Executive Officer [Member]	Dec. 31, 2012 Chief Executive Officer [Member]	Dec. 31, 2011 Chief Executive Officer [Member]	Dec. 31, 2012 Chief Executive Officer [Member]	Aug. 31, 2013 Midcap [Member]	May 31, 2011 Single Institutional Investor [Member]	Jun. 30, 2011 Private Investor [Member]	Jan. 31, 2011 Private Investor [Member]	Mar. 31, 2011 Three Private Investors [Member]	Dec. 31, 2010 Three Private Investors [Member]
Note 9 - Debt and Convertible Debt (Details) [Line Items]
Loans Payable																																				$ 4,400,000
Debt Instrument, Term Loan, Principal Payment Requirements, Net Cash Proceeds													5,000,000	17,500,000
Debtor-in-Possession Financing, Unused Borrowings														1,000,000
Debt Instrument, Interest Rate, Stated Percentage		6.50%							10.00%			1.00%			11.50%															12.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)								1,041,409	500,000					101,531
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item)														3.50
Warrants and Rights Outstanding (in Dollars)														300,000								143,000	77,350														78,000
Debt Instrument, Face Amount		36,000							50,000			260,000
Class of Warrant or Right, Percent Discount Off Exercise Price Per Share									10.00%
Interest Expense, Debt		50,000																										32,990	23,278
Notes Payable																										375,775				600,000
Notes Payable, Fair Value Disclosure																														435,775
Royalty Rate, Percent of Net Sales																														0.60%
Payments to Acquire Intangible Assets						520,000																					60,000
Debt Instrument, Periodic Payment																100,000	120,000	120,000	120,000									80,000
Notes Payable, Current																										140,660
Notes Payable, Noncurrent				376,000	[1]	376,000	[1]			376,000	[1]															235,116
Class Of Warrant or Right, Percent of Coverage												30.00%
Class of Warrant or Right, Maximum Amount of Investment												260,000								1,106,560
Class of Warrant or Right, Percent of Discount												35.00%
Convertible Debt, Fair Value Disclosures (in Dollars)																				221,000
Proceeds from Convertible Debt						266,000																										250,000		79,500	0				100,000		116,705
Debt Instrument, Basis Spread on Variable Rate																																1.50%							2.00%		1.50%
Debt Conversion, Converted Instrument, Shares Issued (in Shares)	142,830																														408,809							120,123
Gains (Losses) on Extinguishment of Debt			(549,000)	(664,000)		(549,000)																									549,480							106,909		7,142
Share Repurchase, Percent of Converted Shares																																						50.00%
Other Liabilities, Current (in Dollars)										150,000														50,000	66,000
Debt Instrument, Term																																24 years
Repayments of Convertible Debt																					19,800										198,000		187,970
Debt Instrument, Convertible, Carrying Amount of Equity Component																															$ 178,200

[1] In March 2012, the Company acquired from MabLife, through an assignment agreement, all rights, titles and interests in and to the patent rights, technology and deliverables related to the anti-Ferritin mAb, AMB8LK, including its nucleotide and protein sequences, its ability to recognize human acid and basic ferritins, or a part of its ability to recognize human acid and basic ferritins. The consideration is as follows: (i) $600,000 payable in six annual installments (one of such installments being an upfront payment made upon execution of the agreement) with a fair value of $435,775 and an interest rate of 12%; and (ii) royalties of 0.6% of net sales of any product containing AMB8LK or the manufacture, use, sale, offering or importation of which would infringe on the patent rights with respect to AMB8LK. Immune is required to assign the foregoing rights back to MabLife if Immune fails to make any of the required payments, is declared insolvent or bankrupt or terminates the agreement. $60,000 was paid to MabLife upon execution of agreement in April 2012 and $32,990 and $23,278 of interest was expensed during the nine months ended September 30, 2013 and 2012, respectively. Future payments are due annually in the following amounts: $80,000 in April, 2013, the payment due date for which has been extended to December 31, 2013, $100,000 in April 2014, and $120,000 on each of the following three anniversaries from April 2015 through April 2017. The present value of future payments is $375,775; $140,660 of which was determined to be short term and $235,116 of which was determined to be long term and has been recorded as notes payable on the balance sheet.